Chaldakov GN, Deyl Z, Vankov VN. Colchicine: possible new application of its antifibrotic (antisecretory) action. Physiol Bohemoslov. 1987;36(1):1-7.
Solak Y, Siriopol D, Yildiz A, Yilmaz MI, Ortiz A, Covic A, et al. Colchicine in renal medicine: New virtues of an ancient friend. Blood Purif. 2017;43(1-3):125-35. doi: 10.1159/000454669.
Chaldakov GN, Nikolov SD. Ultrastructure of the arterial smooth muscle cell. In: Wolf S, Werthessen NT, eds. The Smooth Muscle of the Artery. New York City, NY: Plenum Press. Adv Exp Med Biol 1975;57:14-20.
Chaldakov G, Nikolov S, Vankov V. Fine morphological aspects of the secretory process in arterial smooth muscle cells. II. Role of microtubules. Acta Morph Acad Sci Hung. 1977;25(2-3):167-74.
Chaldakov GN, Kadar A. Microtubules in arterial smooth muscle cells in vivo and in tissue culture. An electron microscope study. In: W. Hauss, R. Wissler, R. Lehman, eds. State of Prevention and Therapy of Human Arteriosclerosis and in Animal Models. Rheinisch-Westfalische Akademie der Wissenschaften, 1978, 211-31.
Chaldakov GN, Nikolov S, Vankov V. Can antitubuhns be antiatherosclerotic agents? A hypothesis based on electron microscope data. In: 6th Hungarian Atherosclerosis Conference. Dobogoko, 10-12.IX.1981. Abstracts, p. 11A.
Chaldakov GN. Antitubulins - a new therapeutic approach for atherosclerosis? Atherosclerosis. 1982;44(3):385-90.
Chaldakov GN, Vankov VN. Morphological aspects of secretion in the arterial smooth muscle cell, with special reference to the Golgi complex and microtubular cytoskeleton. Atherosclerosis. 1986;61(3):175-92.
Chaldakov GN, Vankov VN. Antifibrotic approach in the therapy of arterial occlusive diseases: new considerations. In: G. Trubestein, ed. Conservative Therapy of Arterial Occlusive Disease. Stuttgart and New York, Georg Thieme Verlag, 1986, 224-6.
Chaldakov GN, Grünwald J. Effect of colchicine on the ultrastructure of secretory-state smooth muscle cells from the rabbit artery wall. Exp Pathol. 1987;31(1):1-9.
Chaldakov GN, Nabika T, Nara Y, Yamori Y. Cyclic AMP- and cytochalasin B-induced arborization in cultured aortic smooth muscle cells: its cytopharmacological characterization. Cell Tissue Res. 1989;255(2):435-42.
Chaldakov GN. Anti-inflammatory drugs and ischemic heart disease: new considerations (a cell biologist`s proposal to cardiologists). J Am Coll Cardiol. 1991;17(6):1445-6.
Chaldakov GN. Proposal for clinical trials using anti-inflammatory drugs in the therapy of angina pectoris, myocardial infarction and coronary restenosis after angioplasty and bypass grafting. Med Hypotheses. 1992;37(2):74-5.
Yanev S, Fiore F, Hinev A, Ghenev PI, Hristova MG, Panayotov P, et al. From antitubulins to trackins. Biomed Rev. 2016;27:59-67.
Chaldakov GN, Kisheva AR, Ghenev P. Quo vadis, atherogenesis? Part 1. Smooth muscle cell secretion - may foe become friend in the fight against the vulnerable atherosclerotic plaque. Biomed Rev. 2017;28 (in press).
Vaidya K, Arnott C, MartÃnez GJ, Ng B, McCormack S, Sullivan DR, et al. Colchicine therapy and plaque stabilization in patients with acute coronary syndrome: A CT coronary angiography study. JACC Cardiovasc Imaging. 2017 Oct 14. doi: 10.1016/j.jcmg.2017.08.013.
Lennerz C, Barman M, Tantawy M, Sopher M, Whittaker P. Colchicine for prevention of post-cardiac procedure atrial fibrillation: Meta-analysis of randomized controlled trials. Int J Cardiol 2017;249:127-37. doi: 10.1016/j.ijcard.2017.08.039.
Salih M, Smer A, Charnigo R, Ayan M, Darrat YH, Traina M, et al. Colchicine for prevention of post-cardiac procedure atrial fibrillation: Meta-analysis of randomized controlled trials. Int J Cardiol 2017;243:258-262. doi: 10.1016/j.ijcard.2017.04.022.
Hemkens LG, Ewald H, Gloy VL, Arpagaus A, Olu KK, Nidorf M, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart. 2016;102(8):590-6. doi: 10.1136/heartjnl-2015-308542.
Lee JZ, Singh N, Howe CL, Low S-W, Huang JJ, Ortega G, et al. Colchicine for prevention of post-operative atrial fibrillation. JACC Clin Electrophysiol. 2016;2(1):78-85. doi: 10.1016/j.jacep.2015.09.016.
Campbell KB, Cicci TA, Vora AK, Burgess LD. Beyond gout: Colchicine use in the cardiovascular patient. Hosp Pharm. 2015;50(10):859-67. doi: 10.1310/hpj5010-859.
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61(4):404-10. doi: 10.1016/j.jacc.2012.10.027.
Vogel RA, Forrester JS. Cooling off hot hearts: A specific therapy for vulnerable plaque? J Am Coll Cardiol. 2013;61(4):411-2. doi: 10.1016/j.jacc.2012.10.026.
Alsarah A, Alsara O, Laird-Fick HS. Cardiac manifestations of Familial Mediterranean fever. Avicenna J Med. 2017;7(4):158-63. doi: 10.4103/ajm.AJM_78_17.
Antonopoulos AS, Papanikolaou E, Vogiatzi G, Oikonomou E, Tousoulis D. Anti-inflammatory agents in peripheral arterial disease. Curr Opin Pharmacol. 2017;39:1-8. doi: 10.1016/j.coph.2017.11.001.
Cheng G, Kasiganesan H, Baicu CF, Wallenborn JG, Kuppuswamy D, Cooper G 4th. Cytoskeletal role in protection of the failing heart by β-adrenergic blockade. Am J Physiol Heart Circ Physiol. 2012;302(3):H675-87. doi: 10.1152/ajpheart.00867.2011.
Cheng G, Takahashi M, Shunmugavel A, Wallenborn JG, DePaoli-Roach AA, Gergs Y, et al. Basis for MAP4 dephosphorylation-related microtubule network densification in pressure overload cardiac hypertrophy. J Biol Chem. 2010;285(49):38125-40. doi: 10.1074/jbc.M110.148650.
Email this article (Login required) 
